Skip to main content

Valsartan Recall Urges Some Drug Makers To Increase Prices

Valsartan Recall Urges Some Drug Makers To Increase Prices

When two generic companies manufacturing valsartan recalled hundreds of lots of the blood-pressure medicine last July, Alembic Pharmaceuticals was unaffected by the recall and saw the perfect opportunity to increase prices.  Teva Pharmaceutical and Prinston Pharmaceutical recalled the medications after testing indicated traces of carcinogens in their medications. Making a smart move, Alembic tripled the price of 17 of its own valsartan formulations. According to the data from a healthcare analytics firm, th

Introduction

When two generic companies manufacturing valsartan recalled hundreds of lots of the blood-pressure medicine last July, Alembic Pharmaceuticals was unaffected by the recall and saw the perfect opportunity to increase prices.

Teva Pharmaceutical and Prinston Pharmaceutical recalled the medications after testing indicated traces of carcinogens in their medications. Making a smart move, Alembic tripled the price of 17 of its own valsartan formulations. According to the data from a healthcare analytics firm, the price hikes ranged from 329% to 469%. The Wall Street Journal stated the prices for McCleods Pharmaceuticals’ valsartan products surged as much as 305%. The price hikes affected those consumers who have prescription drug coverage, as they would get high co-pays and premiums next year when insurance companies respond to the price hikes. It is also bad news for those without coverage, as they will not be able to afford costlier medications, and they might compromise on their ongoing treatment altogether by controlling the medication.

Several individuals have already filed valsartan lawsuits seeking fair compensation for their cancer allegedly caused due to N-Nitrosodimethylamine (NDMA) or  N-nitrosodiethylamine (NDEA) contamination in the blood pressure drug. The U.S. Judicial Panel on Multidistrict Litigation last week heard oral arguments on the motion, to centralize product liability claims linked to valsartan recall before a single federal judge for coordinated discovery and other pretrial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!